Target General Information |
Target ID |
T56915
|
Target Name |
HIV Protease |
Species |
Human immunodeficiency virus type 1 (HIV-1) |
UniProt ID |
POL_HV1B1(501-599) |
Sequence |
PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYD QILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF [Human immunodeficie ncy virus type 1 (HIV-1)]
|
Drug and Corresponding Resistance Mutations |
Mutation Info |
Missense: D30N |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[3] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: F53L |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[4], [5], [7] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48L |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48M |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[7], [15], [16] |
Targeted Disease |
HIV infection |
|
|
|
|
Mutation Info |
Missense: G48Q |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48S |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: G48V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[5] |
Targeted Disease |
HIV infection |
|
|
|
|
Mutation Info |
Missense: G73A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
Mutation Info |
Missense: G73C |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
Mutation Info |
Missense: G73S |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
Mutation Info |
Missense: G73T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
Mutation Info |
Missense: I47A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: I47V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: I50L |
Drugs |
|
Mutation Info |
Missense: I50V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18] |
Targeted Disease |
HIV infection |
|
|
|
|
|
Mutation Info |
Missense: I54A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [18], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: I54L |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: I54M |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
|
Mutation Info |
Missense: I54S |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: I54T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: I54V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: I84A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
|
Mutation Info |
Missense: I84C |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
|
Mutation Info |
Missense: I84V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
|
Mutation Info |
Missense: K20T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: K65R |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[23] |
Targeted Disease |
HIV infection |
Mutation Prevalence |
7 out of 37 samples |
|
Mutation Info |
Missense: L10F |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[8], [9], [10] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: L23I |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[21] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: L24F |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[20], [5] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: L24I |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[6] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: L33F |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: L76V |
Drugs |
|
|
|
|
Mutation Info |
Missense: L89V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[4], [13], [14] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: L90M |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[1] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: L90M |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[22] |
Targeted Disease |
HIV infection |
Mutation Prevalence |
1 out of 31 samples |
|
Mutation Info |
Missense: M36I + H69K + L89M |
Drugs |
Drug Name |
Tipranavir |
Drug Info
|
[25] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: M41L |
Drugs |
Drug Name |
Tenofovir + Emtricitabine + Efavirenz |
Drug Info
|
[34] |
|
Mutation Info |
Missense: M46* |
Drugs |
|
Mutation Info |
Missense: M46I |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: M46L |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: M46V |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: N83D |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[5], [11], [12] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: N88D |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[2] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: N88G |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: N88S |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[2] |
Targeted Disease |
HIV infection |
|
|
|
|
Mutation Info |
Missense: N88T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: Q58E |
Drugs |
|
Mutation Info |
Missense: T74P |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
Mutation Info |
Missense: T74S |
Drugs |
Drug Name |
Ritonavir |
Drug Info
|
[24] |
Targeted Disease |
HIV infection |
|
Mutation Info |
Missense: V32I |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: V82A |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[4] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: V82C |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: V82F |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[5] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
Mutation Info |
Missense: V82L |
Drugs |
|
|
Mutation Info |
Missense: V82M |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
Mutation Info |
Missense: V82S |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
Mutation Info |
Missense: V82T |
Drugs |
Drug Name |
Nelfinavir |
Drug Info
|
[17], [19] |
Targeted Disease |
HIV infection |
|
|
|
|
|
|
|
References |
REF 1 |
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039-50.
|
REF 2 |
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998 Oct;42(10):2637-44.
|
REF 3 |
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010 Jan 2;24(1):45-53.
|
REF 4 |
Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003 Jan 1;31(1):298-303.
|
REF 5 |
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61.
|
REF 6 |
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996 Dec;70(12):8270-6.
|
REF 7 |
Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007 Oct;145(1):47-55.
|
REF 8 |
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74.
|
REF 9 |
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008 Nov;80(2):213-22.
|
REF 10 |
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008 Nov;82(21):10366-74.
|
REF 11 |
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inh... J Virol. 2006 Nov;80(21):10794-801.
|
REF 12 |
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther. 2010;15(7):1011-9.
|
REF 13 |
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatme... Antimicrob Agents Chemother. 2008 Feb;52(2):491-6.
|
REF 14 |
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS. 2008 Sep 12;22(14):1809-13.
|
REF 15 |
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS. 2003 May 2;17(7):955-61.
|
REF 16 |
HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol. 2007 May;3(5):e87.
|
REF 17 |
The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98-101.
|
REF 18 |
Tackling the problem of HIV drug resistance. Postepy Biochem. 2016;62(3):273-279.
|
REF 19 |
How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher Biochem J. 2017 Apr 26;474(10):1559-1577.
|
REF 20 |
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother. 2009 Nov;53(11):4869-78.
|
REF 21 |
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.
|
REF 22 |
HIV-1 drug-resistance surveillance among treatment-experienced and -nae patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013 Aug 19;8(8):e71972.
|
REF 23 |
Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. J Antimicrob Chemother. 2016 Jun;71(6):1619-26.
|
REF 24 |
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother. 2009 Nov;64(5):938-44.
|
REF 25 |
Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis. Antiviral Res. 2011 Nov;92(2):213-8.
|
REF 26 |
Personalized HIV therapy to control drug resistance. Drug Discov Today Technol. 2014 Mar;11:57-64.
|
REF 27 |
The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses. 2014 Jul 31;6(8):2960-73.
|
REF 28 |
Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. Viruses. 2014 Sep 24;6(9):3535-62.
|
REF 29 |
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014 Oct 24;6(10):4095-139.
|
REF 30 |
Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS. 2015 Sep;10(5):381-9.
|
REF 31 |
Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol. 2015;10(11):1773-82.
|
REF 32 |
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004 Oct;9(5):695-702.
|
REF 33 |
Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr. 1993;6 Suppl 1:S36-46.
|
REF 34 |
HIV Drug Resistance in Antiretroviral Treatment-Nae Individuals in the Largest Public Hospital in Nicaragua, 2011-2015. PLoS One. 2016 Oct 13;11(10):e0164156.
|